The European Medicines Agency (EMA) has recommended strengthening existing advice to minimize the risks from interactions between Mysimba (naltrexone/bupropion; Orexigen Therapeutics Ireland Limited) and opioid-containing medicines. […]

A drug to treat severe itching in patients with Alagille syndrome should be granted a marketing authorization in the European Union under what the European Medicines […]

Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting of marketing authorization for Anzupgo (delgocitinib; LEO Pharma) to treat moderate to severe chronic […]

The US Food and Drug Administration (FDA) has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib for the treatment of adults with severe alopecia areata. The […]

In its July 2024 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended not granting marketing authorization for […]

The European Medicines Agency (EMA) has recommended that a conditional marketing authorization should be granted for Iqirvo (elafibranor; Ipsen Pharma) for treating primary biliary cholangitis (PBC). […]